精液中的 ангиотензин II 作为在非阻塞性阿佐精子症中预测精子生成活性的预测因素
Iman M Abdelmeniem1, Naglaa Agamia1, Walaa N Roushdy2
1Dermatology, Venereology and Andrology Department, Faculty of Medicine, Alexandria University, 21526 Alexandria, Egypt.
Revista internacional de andrologia
|May 12, 2025
概括
与肥沃对照者相比,非阻性亚精子症 (NOA) 和阻性亚精子症 (OA) 的男性的精液中血管新素II (Ang II) 水平较低. 这表明Ang II可以预测NOA患者接受微型TESE时的精子存在.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
背景情况:
- 非阻塞性精症 (NOA) 缺乏可靠的非侵入性标记物来预测精子生成潜力.
- 在NOA中识别成熟的精子对于成功的微型TESE结果至关重要.
- 精液中的 ангиотензин II (Ang II) 是一种与精子参数相关的潜在生物标志物.
研究的目的:
- 调查精子Ang II水平与男性不孕症中的精子生成活性之间的关系.
- 评估精子Ang II作为NOA中的精子检索预测标记物的潜力.
主要方法:
- 一项前性病例控制研究,涉及90名男性.
- 分析了三个组:30名NOA患者,30名阻塞性亚精子症 (OA) 患者和30名健康的肥沃对照.
- 测量和比较跨组的精液Ang II水平.
主要成果:
- 与对照组相比,OA和NOA患者的精液Ang II水平显著降低 (p < 0.001).
- NOA患者的Ang II水平明显低于对照组 (p < 0.001).
- 在NOA中,Ang II水平有所变化,在单细胞塞尔托利综合征中最低,在晚期成熟停止时最高 (p ≤0.05).
结论:
- 精液中的Ang II水平在患有亚精子症的男性中显著降低.
- 精子Ang II可以作为一个有价值的非侵入性预测标志物用于精子生成.
- 这种标记物可以帮助识别通过微型TESE在NOA中成功检索精子的候选人.
相关概念视频
Spermatogenesis
101.8K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
101.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
383
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
383
Infertility in Males
176
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
176
Antihypertensive Drugs: Angiotensin II Receptor Blockers
539
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
539
Antihypertensive Drugs: Direct Renin Inhibitors
443
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
443
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316


